Telomerase as a diagnostic and therapeutic target for cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 2, 2002, Pages 217-225

  Doyle, L Austin ^a   Highsmith, W Edward ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Antisense RNA; Ribonucleoprotein; Ribozyme; Telomerase; Telomere

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CANCER VACCINE; DIDEOXYGUANOSINE; GELDANOMYCIN; NUCLEOSIDE ANALOG; RIBONUCLEOPROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; CELL IMMORTALIZATION; CHROMOSOME; CONTROLLED STUDY; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOMATIC CELL; TELOMERE;

EID: 0036084491     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.2.217     Document Type: Review

References (71)

1. Reconstitution of human telomerase with the catalytic protein subunit hTRT
2. Telomerase catalytic subunit homologs from fission yeast and humans
3. Telomere loss: Mitotic clock or genetic time bomb?
4. A role for both RB and p53 in the regulation of human cellular senescence
5. Inhibition of telomerase limits the growth of human cancer cells
6. Specific association of human telomerase activity with immortal cells and cancer
7. Agents that target telomerase and telomeres
8. Modification of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity
9. Comparison of the Telomeric Repeat Amplification Protocol (TRAP) to the new TRAPeze telomerase detection kit
10. Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates
11. Telomerase activity in lesions of the thyroid: Application to diagnosis of clinical samples including fine-needle aspirates
12. Telomerase activity in human gynaecological malignancies
13. Role of telomerase in cell senescence and oncogenesis
14. Telomerase detection in bodily fluids
15. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine
16. Telomerase activity and in situ telomerase RNA expression in malignant and non-malignant lymph nodes
17. Telomerase activity in benign endometrium and endometrial carcinoma
18. Telomerase activity in normal and malignant hematopoietic cells
19. Development of retinoblastoma in the absence of telomerase activity
20. Differential telomerase expression in human primary intracranial tumors
21. Telomerase activity in human brain tumours
22. Correlating telomerase activity levels with human neuroblastoma outcomes
23. Molecular biological observations in gastric cancer
24. Correlation of telomerase activity with development and progression of adult T-cell leukemia
25. Telomerase activity in ordinary meningiomas predicts poor outcome
26. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas
27. Telomerase activity in human breast tumors
28. Detection of circulating carcinoma cells by telomerase activity
29. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients
30. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues
31. Telomeres and telomerase in normal and malignant haematopoietic cells
32. The RNA component of human telomerase
33. A hexameric phosphorothionate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
34. RNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules
35. Inhibition of human telomerase activity by peptide nucleic acids
36. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
37. Treatment of prostate cancer in vitro and in vivo with 2-5A-antitelomerase RNA component
38. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cells
39. The therapeutic potential of ribozymes
40. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
41. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
42. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
43. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
44. Effects of reverse transcriptase inhibitors on telomere length and telomerase activit in two immortalized human cell lines
45. Identification of Mad as a repressor of the human telomerase (hTERT) gene
46. Adenoviral expression of p53 represses telomerase activity through downregulation of human telomerase reverse transcriptase transcription
47. Functional requirement of p23 and Hsp90 in telomerase complexes
48. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
49. The DNA structures at the ends of eukaryotic chromosomes
50. Inhibition of telomerase by G-quartet DNA structures
51. Thermally induced DNA-RNA hybrid to G-quadruplex transitions: Possible implications for telomere synthesis by telomerase
52. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells
53. Human telomerase inhibition by 7-deaza-2′deoxypurine nucleoside triphosphates
54. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors
55. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis
56. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes
57. Cytotoxic T-cell imunity against telomerase reverse transcriptase in humans
58. Induction of cytotoxic T-cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA-transfected dendritic cells
59. Secondary structure of vertebrate telomerase RNA
60. Preclinical and clinical strategies for development of telomerase and telomere inhibitors
61. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays
62. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay
63. In vitro tumour growth inhibition by telomerase antisense and anticancer agents
64. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells
65. Telomerase assay for differentiating between malignancy related and nonmalignant ascites
66. Detection of ovarian cancer cells: Comparison of a telomerase assay and cytologic examination
67. Telomerase activity in lung cancer cells obtained from bronchial washings
68. Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease
69. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
70. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
71. Comparison of screening methods in the detection of bladder cancer